

## United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
10/017,451	12/18/2001	Octavian Barzu	217489US0 6379		
22850 7	7590 10/03/2003		EXAMINER		
OBLON, SPIVAK, MCCLELLAND, MAIER & NEUSTADT, P.C. 1940 DUKE STREET			MONSHIPOURI, MARYAM		
	A, VA 22314	ART UNIT	PAPER NUMBER		
			1652		
			DATE MAILED: 10/03/2003	ì	

Please find below and/or attached an Office communication concerning this application or proceeding.

	A. M. A	Application No.	\	Applicant(s)				
Office Action Summary		10/017,451		BARZU ET AL.				
		Examin r		Art Unit				
		Maryam Monship	oouri	1652				
The MAILING DATE of this communication appears on the cover sheet with the correspondence address								
Period for Reply								
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.  - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).  - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).  Status								
	Responsive to communication(s) filed on							
·								
,	, <b>/—</b>			osecution as to th	e merits is			
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213. <b>Disposition of Claims</b>								
4)⊠ Claim(s) <u>1-18</u> is/are pending in the application.								
4a) Of the above claim(s) is/are withdrawn from consideration.								
5) Claim(s) is/are allowed.								
6) Claim(s) is/are rejected.								
7) 🗌 (	Claim(s) is/are objected to.							
8) Claim(s) 1-18 are subject to restriction and/or election requirement.								
Application	•							
·	9) The specification is objected to by the Examiner.							
10) ☐ The drawing(s) filed on is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.								
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).								
11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.								
If approved, corrected drawings are required in reply to this Office action.  12) The oath or declaration is objected to by the Examiner.								
Priority under 35 U.S.C. §§ 119 and 120								
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).								
a) ☐ All b) ☐ Some * c) ☐ None of:								
1.☐ Certified copies of the priority documents have been received.								
Certified copies of the priority documents have been received in Application No								
3. Copies of the certified copies of the priority documents have been received in Application No								
application from the International Bureau (PCT Rule 17.2(a)).  * See the attached detailed Office action for a list of the certified copies not received.								
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).								
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.								
Attachment(s)								
2) Notice	of References Cited (PTO-892) of Draftsperson's Patent Drawing Review (PTO-948) ation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) 🔲		(PTO-413) Paper No( atent Application (PT				

Application/Control Number: 10/017,451

Art Unit: 1652

Restriction to one of the following inventions is required under 35 U.S.C. 121:

- I. Claims 1-8 and 18, drawn to polynucleotides encoding a UMP kinase, vectors and host cells comprising said polynucleotides and methods of expressing said polynucleotides, classified in class 435, subclass 194.
- II. Claims 9, and 11, drawn to methods of assaying said kinase using GTP, classified in class 435, subclass 194.
- III. Claims 10, and 11, drawn to methods of assaying UMP kinase using UTP, classified in class 435, subclass 194.
- IV. Claims 12-14, drawn to methods of modulating said kinase, classified in class435, subclass 15.
- V. Claim 15, drawn to methods of screening for modulators of said kinase, classified in class 435, subclass 15.
- VI. Claims 16-17, drawn to modulators of said kinase, classification unknown. This is because applicant has not defined the chemical structure of said modulators and classification is based on chemical structure of said modulators..

The inventions are distinct, each from the other because of the following reasons:

The DNA of Group I and the modulators of Group VI are patentably distinct because each invention is directed to a product of unrelated chemical structure and function.

The DNA of Group I is unrelated to any of the methods of Groups II-V because said product is neither made not used by any of said methods.

Art Unit: 1652

The modulators of Group VI are unrelated to any of the methods of Groups II-IV because said products are neither made not used by any of said methods.

Inventions V and VI and are related as product and process of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the modulators of Group VI may be used in treatment of diseases caused by said UMP kinase which is a totally different method than that of Group V.

The inventions of Groups II-V are patentably distinct each from the other because each method has different steps and different end-points.

Because these inventions are distinct for the reasons given above and have acquired a separate status in the art because of their recognized divergent subject matter, restriction for examination purposes as indicated is proper.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any

Application/Control Number: 10/017,451

Page 4

Art Unit: 1652

amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Maryam Monshipouri Ph.D. whose telephone number is (703) 308-1083. The examiner can normally be reached on Monday-Friday from 8:00 AM to 4:30 PM. If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor Dr. P. Achutamurthy, can be reached at (703) 308-3804.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the Technology Center 1600 receptionist whose telephone number is (703) 308-0196.